ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company's drug candidate and is a treatment for lupus, and life threatening auto immune disease. The Company's treatment for cancer, IPP-204106, has completed a Phase I/IIa study in cancer patients in France. Its compound IPP-102199 for pain relief is designed as a non-addictive replacement for morphine and other opioids, and is in pre-clinical development. Its treatment for inflammatory and allergic disorders (IPP-201007) is in early stage development. Its compound IPP-203101 is an antibiotic against methicillin-resistant staphylococcus aureus (MRSA) and other infections. The Company's research operations are in France.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: LON:IMM
- CUSIP: N/A
- Web: www.immupharma.org/
- Market Cap: £75.54 million
- Outstanding Shares: 132,522,000
- 50 Day Moving Avg: GBX 53.24
- 200 Day Moving Avg: GBX 53.83
- 52 Week Range: GBX 31.44 - GBX 70.32
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: $164,783.00
- Price / Sales: 458.41
- Book Value: GBX 0.04 per share
- Price / Book: 14.25
- EBIDTA: ($6,470,000.00)
- Net Margins: -977.88%
- Return on Equity: -53.96%
- Return on Assets: -45.00%
- Average Volume: 204,432 shs.
Frequently Asked Questions for ImmuPharma PLC (LON:IMM)
What is ImmuPharma PLC's stock symbol?
ImmuPharma PLC trades on the London Stock Exchange (LON) under the ticker symbol "IMM."
When will ImmuPharma PLC make its next earnings announcement?
Where is ImmuPharma PLC's stock going? Where will ImmuPharma PLC's stock price be in 2017?
2 brokerages have issued 12-month price objectives for ImmuPharma PLC's shares. Their forecasts range from GBX 100 to GBX 181. On average, they expect ImmuPharma PLC's stock price to reach GBX 140.50 in the next year. View Analyst Ratings for ImmuPharma PLC.
Who are some of ImmuPharma PLC's key competitors?
Some companies that are related to ImmuPharma PLC include Agile Therapeutics (AGRX), Recro Pharma (REPH), AcelRx Pharmaceuticals (ACRX), Cidara Therapeutics (CDTX), Cellular Biomedicine Group (CBMG), Axsome Therapeutics (AXSM), MannKind Corporation (MNKD), Verastem (VSTM), Fate Therapeutics (FATE), ProQR Therapeutics N.V. (PRQR), OncoCyte Corp (OCX), Summit Therapeutics PLC (SUMM), Vascular Biogenics (VBLT), Adverum Biotechnologies (ADVM), Arrowhead Pharmaceuticals (ARWR), Vital Therapies (VTL), Pfenex (PFNX) and MEI Pharma (MEIP).
Who are ImmuPharma PLC's key executives?
ImmuPharma PLC's management team includes the folowing people:
- Robert Henri Zimmer M.D., Ph.D., President, Chief Scientific Officer, Director
- Dimitri F. Dimitriou, Chief Executive Officer, Director
- Tracy Weimar, Vice President - Operations and Finance, Company Secretary
- Timothy McCarthy, Non-Executive Chairman of the Board
- Stephane Robert Mery, Non-Executive Director
How do I buy ImmuPharma PLC stock?
Shares of ImmuPharma PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is ImmuPharma PLC's stock price today?
MarketBeat Community Rating for ImmuPharma PLC (LON IMM)MarketBeat's community ratings are surveys of what our community members think about ImmuPharma PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of ImmuPharma PLC stock can currently be purchased for approximately GBX 57.
Consensus Ratings for ImmuPharma PLC (LON:IMM) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||GBX 140.50|
Analysts' Ratings History for ImmuPharma PLC (LON:IMM)
(Data available from 7/23/2015 forward)
|6/30/2017||Northland Securities||Boost Price Target||Buy||GBX 171 -> GBX 181|
|4/20/2017||Panmure Gordon||Reiterated Rating||Buy||GBX 100|
|7/20/2016||Northland Capital Partners||Initiated Coverage||Buy||GBX 171|
Earnings History for ImmuPharma PLC (LON:IMM)Earnings History by Quarter for ImmuPharma PLC (LON IMM)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for ImmuPharma PLC (LON:IMM)
Current Year EPS Consensus Estimate: $-4.26 EPS
Dividend History for ImmuPharma PLC (LON:IMM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for ImmuPharma PLC (LON:IMM)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for ImmuPharma PLC (LON:IMM)
Latest Headlines for ImmuPharma PLC (LON:IMM)
ImmuPharma PLC (IMM) Chart for Sunday, July, 23, 2017